Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Aurinia Pharmaceuticals Inc AUPH

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.


NDAQ:AUPH - Post by User

Comment by jboom70on Dec 04, 2021 5:59pm
286 Views
Post# 34199059

RE:RE:RE:WTH ? Happened today ?

RE:RE:RE:WTH ? Happened today ?New suitor reported again. Short term price changes are just games with the shorts, they have beat this thing hard and won't let it alone.

No matter a BO is a set price. This was designed to sell.

Prospectus was to replace old one for good house keeping.

<< Previous
Bullboard Posts
Next >>